Keum Young Ahn
Komipharm International (South Korea)(KR)
Publications by Year
Research Areas
Biosimilars and Bioanalytical Methods, Lymphoma Diagnosis and Treatment, Virus-based gene therapy research, Herpesvirus Infections and Treatments, HER2/EGFR in Cancer Research
Most-Cited Works
- → Human cytomegalovirus inhibits antigen presentation by a sequential multistep process.(1996)377 cited
- → Engineered Human Ferritin Nanoparticles for Direct Delivery of Tumor Antigens to Lymph Node and Cancer Immunotherapy(2016)93 cited
- → Inhibition of MHC class I antigen presentation by viral proteins(1997)55 cited
- → Ammonia Removal Using Hepatoma Cells in Mammalian Cell Cultures(2000)23 cited
- → Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study(2021)13 cited
- → Safety of Live Attenuated ASFV‐G‐ΔI177L/ΔLVR Vaccination in Sows With Advanced Pregnancies(2025)4 cited
- → African Swine Fever Vaccine Candidate ASFV-G-ΔI177L/ΔLVR Protects Against Homologous Virulent Challenge and Exhibits Long-Term Maintenance of Antibodies(2025)4 cited
- → Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months(2019)3 cited
- → Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea(2022)2 cited
- → Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study(2024)2 cited